Stockscreener 앱 받기
7.27
0.95%
-0.07
시간 외 거래:
7.29
0.02
+0.28%
전일 마감가:
$7.34
열려 있는:
$7.45
하루 거래량:
630.80K
Relative Volume:
0.53
시가총액:
$1.00B
수익:
$62.04M
순이익/손실:
$-533.34M
주가수익비율:
-1.6192
EPS:
-4.49
순현금흐름:
$-473.07M
1주 성능:
-1.76%
1개월 성능:
-10.80%
6개월 성능:
-17.85%
1년 성능:
-30.83%
1일 변동 폭
$7.24
$7.60
1주일 범위
$7.22
$7.64
52주 변동 폭
$6.56
$13.09
비르 바이오테크 Stock (VIR) Company Profile
명칭
Vir Biotechnology Inc
전화
415-906-4324
주소
1800 OWENS STREET, SAN FRANCISCO, CA
VIR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
7.27 | 1.00B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.76 | 104.50B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.19 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.16 | 37.08B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.62 | 30.13B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.30 | 27.64B | 3.30B | -501.07M | 1.03B | -2.1146 |
비르 바이오테크 Stock (VIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-03-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-02-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 개시 | SVB Leerink | Outperform |
| 2022-09-09 | 개시 | Morgan Stanley | Underweight |
| 2022-03-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-01-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-09-14 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 개시 | Needham | Buy |
| 2020-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-02-27 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 개시 | Robert W. Baird | Neutral |
| 2019-11-05 | 개시 | Barclays | Overweight |
| 2019-11-05 | 개시 | Cowen | Outperform |
| 2019-11-05 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | JP Morgan | Overweight |
모두보기
비르 바이오테크 주식(VIR)의 최신 뉴스
State Street Corp Purchases 530,645 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Y Intercept Hong Kong Ltd Reduces Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Long Term Trading Analysis for (VIR) - Stock Traders Daily
Vir Biotechnology's SWOT analysis: stock poised for growth amid hepatitis breakthroughs - Investing.com
GlaxoSmithKline & Vir Biotechnology's Sotrovimab Antibody Cleared for Emergency Use in the U.S. - Oficjalny Portal Gminy Brzesko
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January (VIR) - Seeking Alpha
Vir Biotechnology's drugs receive FDA and EMA nods - Investing.com India
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta - BioSpace
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
(VIR) Trading Signals - Stock Traders Daily
Vir Biotechnology EVP vanina de Verneuil sells $624 in stock By Investing.com - Investing.com Canada
Vir Biotechnology EVP vanina de Verneuil sells $624 in stock - Investing.com
Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX) - StreetInsider.com
Vir Biotechnology (NASDAQ:VIR) three-year losses have grown faster than shareholder returns have fallen, but the stock surges 12% this past week - Simply Wall St
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely? - Yahoo Finance
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs - BioSpace
Vir Biotechnology's SWOT analysis: stock poised for growth amid clinical progress - Investing.com
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference - BioSpace
Vir Biotechnology CEO to Present at Evercore ISI HealthCONx Conference | VIR Stock News - StockTitan
Leerink Partnrs Has Pessimistic View of VIR FY2026 Earnings - MarketBeat
HC Wainwright Has Optimistic Outlook of VIR FY2024 Earnings - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology poised for outperformance, keeps buy rating on pipeline potential - Investing.com UK
Empowered Funds LLC Sells 163,723 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
500: Something went wrong - Investing.com India
Vir Biotechnology holds a virtual investor update - Nasdaq
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - BioSpace
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BioSpace
VIRVir Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial | VIR Stock News - StockTitan
EMA grants orphan drug status to Vir Biotech hepatitis treatments - Investing.com
EMA grants orphan drug status to Vir Biotech hepatitis treatments By Investing.com - Investing.com Canada
Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - StreetInsider.com
Vir Biotechnology stock hits 52-week low at $7.08 - Investing.com
Vir Biotechnology stock hits 52-week low at $7.08 By Investing.com - Investing.com UK
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat
(VIR) Proactive Strategies - Stock Traders Daily
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance
Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com
Vir Biotechnology Inc. (VIR) Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations - StreetInsider.com
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire
Baillie Gifford & Co. Reduces Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology's EVP sells shares worth $44,453 - Investing.com India
Vir Biotechnology's EVP sells shares worth $44,453 By Investing.com - Investing.com UK
Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares - Investing.com India
Leerink Partnrs Has Negative Outlook of VIR FY2024 Earnings - MarketBeat
HC Wainwright Expects Lower Earnings for Vir Biotechnology - MarketBeat
비르 바이오테크 (VIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
자본화:
|
볼륨(24시간):